Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Impact · against what's priced in

Zymeworks' presentation of Phase 1 dose-optimization data for ZW191 at ESMO 2026 provides a positive clinical update for its FRα-targeting ADC. This progress supports the company's pipeline advancement and may catalyze future trial designs or partnership discussions.

ZYME+0.30: No priced-in read yet

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

What matters in this story

How each ticker is affected

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

What matters in this story

How each ticker is affected

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Track these names every morning.

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Track these names every morning.

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity